To investigate the effect of dexamethasone therapy on serum vitamin E concentrations in premature infants with bronchopulmonary dysplasia.
INTRODUCTION
Vitamin E, a major biological antioxidant, inhibits peroxidation of membrane lipids by scavenging free radicals. 1 Vitamin E has been extensively investigated for the prevention and treatment of retinopathy of prematurity (ROP) at physiological (1 to 3 mg/dl) and pharmacological (3 to 5 mg/dl) serum concentrations with conflicting results. [2] [3] [4] [5] [6] [7] [8] A recently conducted meta-analysis of the published randomized clinical trials of vitamin E prophylaxis to reduce ROP demonstrated a decreased incidence for Stage 3+ROP in the vitamin E treated group as compared to the control group. 9 Based on the findings of this meta-analysis, it has been suggested that the role of vitamin E in reducing severe ROP in premature infants should be re-evaluated.
Currently, there are conflicting results on the effect of dexamethasone on the incidence of ROP. [10] [11] [12] [13] Dexamethasone is known to increase serum concentrations of vitamin A, but its effect on concentrations of vitamin E, which is also a fat-soluble vitamin, has not been previously described. 14, 15 We describe a clinicallaboratory observation of the effect of dexamethasone on vitamin E concentrations during a prospective clinical study conducted to investigate lipid intolerance in neonates on dexamethasone therapy for bronchopulmonary dysplasia. 16 
METHODS
The 10 premature infants enrolled in a prospective study designed to evaluate the effect of dexamethasone on lipid intolerance were eligible for the study. 16 The subjects were enrolled between November 1995 and July 1997. This study was approved by Institutional Research Review Board of University of Rochester and informed consent was obtained from the parents. The study was prospective with patients serving as their own controls. The subjects were between 24 and 29 weeks' gestational age (GA) at birth and had early BPD at the time of study. GA was assessed by obstetric history, or if obstetric history was unreliable, by the Ballard examination. The diagnosis of BPD was determined by the clinical staff based on chest radiographs and increasing FiO 2 requirements.
Dexamethasone was used at the discretion of the attending neonatologist. Dexamethasone therapy followed the protocol of Avery: 0.25 mg/kg every 12 hours for the first six doses, followed by 0.15 mg/kg every 12 hours for the next six doses, and a gradual wean thereafter. 17 To evaluate lipid metabolism, patients with a known genetic disorder, active infection, prior lipid intolerance, thyroid problems, surgery within 72 hours of the study, bleeding manifestations and patients requiring an epinephrine or insulin drip were excluded. During the study period, for 5 days after initiation of dexamethasone therapy, lipid intake was kept constant unless hypertriglyceridemia (triglyceride levels >250 mg/dl (2.82 mmol/l)) developed.
Eight of these 10 infants had serum vitamin E (a tocopherol) concentrations measured at baseline (before the start of dexamethasone therapy) and within 5 days of the initiation of dexamethasone therapy (post-dex). Serum vitamin E concentrations are routinely measured in our unit to monitor vitamin E status of premature infants. Serum vitamin E concentrations were measured by high-performance liquid chromatography (HPLC). Serum triglyceride concentrations, measured simultaneously with vitamin E, before and after the initiation of dexamethasone therapy, were also available for each of the eight infants. Serum triglyceride concentrations were measured using a standard colorimetric method (Ortho Clinical Diagnostics, Raritan, NJ). Vitamin E/triglyceride ratios were calculated for each of these eight subjects. Charts were reviewed for vitamin E intake at baseline and during the study interval (post-dex). Charts were also reviewed for clinical findings, suggesting vitamin E deficiency or toxicity such as generalized edema, thrombocytosis, necrotizing enterocolitis (NEC) and sepsis during the study period.
Statistical Analysis
Wilcoxon's signed-rank test was used to analyze paired measurements with the hypothesis that the mean difference between the paired measurements is zero (Stata Program; Stata Corporation, College Station, TX). Correlation analysis was performed using Spearman's correlation. All tests were two-sided and a p-value of <0.05 was considered statistically significant.
RESULTS
The mean postmenstrual age of the eight infants at the initiation of dexamethasone therapy was 28 4/7 weeks (range, 27 3/7 to 29 4/7 weeks) with a mean chronological age of 17 days (range, 10 to 28 days). All eight infants were appropriate for GA. Six out of the eight infants were female. There were no significant differences in the mean postmenstrual age and the mean chronological age between six infants, in whom vitamin E concentrations rose following dexamethasone therapy and two infants in whom it did not. Both the infants in whom vitamin E concentration did not increase following dexamethasone therapy were female. There was no significant difference in the mean vitamin E intake between baseline (2.8 U/kg/day) and post-dexamethasone therapy (2.2 U/kg/day) among the eight infants (Table 1 , p ¼ 0.27). None of these eight infants were receiving any supplemental vitamin E therapy prior to dexamethasone therapy. Mean serum vitamin E concentrations, triglyceride concentrations and vitamin E:triglyceride ratios at baseline and after the initiation of dexamethasone therapy among the study subjects are shown in Table 1 . There was an increase in vitamin E concentrations in seven of eight neonates after dexamethasone therapy with a mean vitamin E concentration on dexamethasone (3.5 mg/dl) significantly higher than the mean baseline vitamin E concentration (2.1 mg/dl) ( Figure 1 , Table 1 ). All neonates had physiological serum vitamin E concentrations (1 to 3 mg/dl) at baseline, while six of eight infants had pharmacological serum vitamin E concentrations (Z3 mg/dl) on dexamethasone ( Figure 1 ). All infants with an increase in serum vitamin E concentrations also had a simultaneous increase in serum triglyceride concentrations with a significant correlation between vitamin E and triglyceride concentrations (p ¼ 0.005, Spearman's r ¼ 0.92) (Figure 2 ). Vitamin E:triglyceride ratios were similar before and after the initiation of dexamethasone therapy. None of the infants had clinical evidence of vitamin E deficiency or toxicity. 
DISCUSSION
Our study demonstrates that dexamethasone therapy causes an acute increase in serum vitamin E concentrations, independent of vitamin E intake. A similar effect on vitamin A, also a fat-soluble vitamin, has been demonstrated previously. 14, 15 Both vitamins A and E are stored in adipose tissue and liver. However, compared to the circulating vitamin A, which is bound to retinol binding protein and transthyretin, vitamin E is primarily circulated bound with lipoproteins. The mechanism by which steroids increase serum vitamin E concentrations has not been studied. We speculate that the increase in serum vitamin E concentration observed with dexamethasone usage may be secondary to the increase in serum lipids, or independently by causing the release of vitamin E from storage sites. It has been previously shown that with the increase in serum lipids, vitamin E appears to be released from the cellular membrane compartment into circulating lipoprotein, increasing the absolute concentrations of plasma vitamin E. 18 Because of this relation with serum lipids, it has been suggested that the ratio of vitamin E to total lipid or vitamin E to lipid fraction may be a more useful way to measure vitamin E status. 19, 20 However, there is little information available regarding optimum ratios for vitamin E to total lipid or vitamin E to lipid fraction (triglyceride or cholesterol) in premature infants.
Although six out of eight infants had an increase in vitamin E concentrations to a pharmacological concentration on dexamethasone therapy, ratios of vitamin E to triglyceride were not increased on this therapy. Moreover, only infants with increases in serum triglyceride concentrations on dexamethasone therapy had increases in serum vitamin E concentrations. This indicates that an increase in the serum vitamin E concentration is partly due to an increase in serum lipid levels.
Hypertriglyceridemia following dexamethasone therapy has been recently demonstrated in premature infants. 16, 21 In these studies, occurrence of hypertriglyceridemia was dependent on the dexamethasone dosage. A decrease in triglyceride concentration was observed with a decrease in dexamethasone dosage. 16 Because of the marked dependence of plasma vitamin E values on lipid concentration, we speculate the effect of dexamethsone on vitamin E concentrations to be also dose dependent.
In neonates, prolonged exposure to pharmacological serum concentrations of vitamin E has been associated with an increased incidence of late-onset sepsis and NEC. 8 None of the study subjects had sepsis or NEC during the study period. Premature infants are at an increased risk for the development of the clinical syndrome of vitamin E deficiency, which is characterized by generalized edema, hemolytic anemia, reticulocytosis and thrombocytosis. 22 Since none of these infants had clinical evidence of vitamin E deficiency during the study period, we can presume the ratios observed do not suggest vitamin E deficiency.
In summary, dexamethasone increases the absolute concentration of vitamin E but not lipid adjusted vitamin E concentrations. Future studies evaluating the role of steroids or vitamin E in reducing ROP should take into consideration the interaction between dexamethasone and serum vitamin E concentrations. The usefulness of vitamin E to total lipid or vitamin E to lipid fraction at pharmacological vitamin E levels also needs to be investigated in premature infants while evaluating the beneficial or toxic effects of vitamin E. Figure 2 . Serum triglyceride concentrations at baseline (pre-dex) and after (post-dex) the initiation of dexamethasone therapy for each individual subjects.
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